Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma

October 30, 2018

Follow-on drugs, also referred to as ‘next-generation drugs’, are ‘an established practice’ among drug innovators. They are one of the most effective R&D strategies implemented by drug innovators, and can be considered a cannibalization or switching strategy. In a nutshell, it is a timely switch from a mature/firstgeneration drug to its next-generation, improved version. Given the fixed patent term and limited market exclusivity of drugs, cannibalization has been instrumental in maintaining the market share for drug makers.

Spotlight

APPI Health Group

The APPI has enjoyed immense success with training Physiotherapists and equivalent degree therapists in the APPI Pilates method. Our success relies on our research based approach to Pilates training. As physiotherapists, we recognise the demand for more specific Pilates training which targets the higher theoretical and practical experience of higher degree therapists. The APPI method presents the most current research relevant to Pilates and teaches a realistic framework of exercises to apply in the clinical setting.

OTHER WHITEPAPERS
news image

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

Application Notes & Whitepapers 2019

whitePaper | December 19, 2019

Welcome to European Pharmaceutical Review’s Application Notes & Whitepapers Supplement 2019. This year’s topics range from analytical techniques for bioprocess investigation, host cell protein analysis and Raman imaging to advice on outsourcing services for product characterisation.

Read More
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Read More
news image

Transforming Patient Journey in Clinical Trials

whitePaper | April 7, 2022

Year after year, the Life Sciences industry expands at a breakneck pace, with pharmaceutical development leading the way.

Read More

Spotlight

APPI Health Group

The APPI has enjoyed immense success with training Physiotherapists and equivalent degree therapists in the APPI Pilates method. Our success relies on our research based approach to Pilates training. As physiotherapists, we recognise the demand for more specific Pilates training which targets the higher theoretical and practical experience of higher degree therapists. The APPI method presents the most current research relevant to Pilates and teaches a realistic framework of exercises to apply in the clinical setting.

Events